Keeping your options open is becoming the thing to do in biotech.
Many boards of private drug developers are electing to simultaneously seek an IPO …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
When pharma companies pull out of gene therapy programmes, nonprofit organisations are taking matters into their own hands. Credit: afry_harvy via Shutterstock. The development of
Cronos Group Reports 2023 First Quarter Results Industry-leading balance sheet with $836 million in cash and short-term investments Targeting positive cash flow in 2024 Net